Developed DMN (%) (n=9,006) Did not develop DMN (%) (n=40,355)
p value
Cox regression Hazard Ratio (95% CI)
p value
Mean age, years (SD) 53.8 (10.1) 51.4 (12.3) <0.001 1.03 (1.03-1.03) <0.001
Male Gender 7,443 (82.6%) 30,433 (75.4%) <0.001 1.24 (1.17-1.31) <0.001
Race Caucasian African American Hispanic Asian Other Unknown 7,600 (84.4%) 914 (10.1%) 336 (3.7%) 90 (1.0%) 56 (0.6%) 10 (0.1%) 29,624 (73.4%) 6,578 (16.3%) 2,740 (6.8%) 988 (2.4%) 412 (1.0%) 139 (0.03%)
<0.001
Ref 1.05 (0.97-1.13) 0.78 (0.70-0.87) 0.68 (0.55-0.84) 0.90 (0.69-1.17) 1.16 (0.55-2.44) 0.2 <0.001 <0.001 0.4 0.7
Diagnosis at Listing Dilated Myopathy Restrictive Hypertrophic Prior graft failure CAD Valvular Disease Congenital Other 5,552 (61.6%) 96 (1.1%) 66 (0.7%) 204 (2.3%) 2,591 (28.8%) 255 (2.8%) 91 (1.0%) 117 (1.3%) 30,363 (75.2%) 776 (1.9%) 745 (1.8%) 873 (2.2%) 5,020 (12.4%) 953 (2.4%) 939 (2.3%) 624 (1.5%)
<0.001
Ref 0.99 (0.80-1.21) 0.75 (0.59-0.96) 1.66 (1.25-2.21) 1.03 (0.97-1.08) 0.88 (0.77-0.99) 0.89 (0.72-1.10) 1.19 (0.98-1.44) 0.9 0.02 0.001 0.4 0.04 0.3 0.08
Year Transplanted 1987 –2004 2005 – 2018 Ref 1.05 (0.87-1.27)
0.6
Comorbidities Mean BMI, kg/m2 (SD) Mean GFR, mL/min/1.73m2 (SD) Diabetes History smoking Cerebrovascular Disease 25.8 (4.3) 66.1 (23.9) 1,057/4,930 (21.4%) 1,050/1,783 (58.9%) 195/4,913 (4.0%) 26.5 (4.8) 70.6 (26.0) 7,936/33,988 (23.3%) 9,910/21,403 (46.3%) 1,581/33,772 (4.7%) <0.001 <0.001 <0.001 <0.001 <0.001 1.00 (1.00-1.01) 0.99 (0.99-0.99) 0.99 (0.93-1.07) 1.39 (1.27-1.53) 0.98 (0.85-1.13) 0.3 <0.001 0.9 <0.001 0.8
Infectious Disease Serology HBV Core Ab (+) HCV (+) CMV (+) EBV (+) 244/5,630 (4.3%) 118/6,112 (1.9%) 1,957/3,136 (62.4%) 2,186/2,845 (76.8%) 1,378/31,422 (4.4%) 720/34,377 (2.1%) 16,251/26,732 (60.8%) 19,939/22,955 (86.9%) <0.001 <0.001 <0.001 <0.001 1.19 (1.04-1.35) 1.01 (0.84-1.22) 0.56 (0.39-0.82) 0.91 (0.81-1.02) 0.01 0.9 0.003 0.1
Induction Therapy Basiliximab ATG 6,104 (67.8%) 451 (5.0%) 909 (10.1%) 30,280 (75.0%) 5,662 (14.0%) 6,602 (16.4%) <0.001 <0.001 <0.001 0.98 (0.92-1.05) 0.98 (0.88-1.09) 1.00 (0.93-1.08) 0.6 0.7 0.9
Maintenance Therapy Calcineurin inhibitor mTOR inhibitor MMF Steroid 6,918 (76.8%) 123 (1.4%) 3,249 (36.1%) 7,064 (78.4%) 36,771 (91.1%) 773 (1.9%) 27,156 (67.3%) 36,107 (89.5%) <0.001 <0.001 <0.001 <0.001 0.91 (0.82-1.01) 0.85 (0.71-1.03) 0.89 (0.83-0.96) 1.03 (0.94-1.13) 0.07 0.09 0.001 0.5
Post-Op Complications Stroke Dialysis 82/5,050 (1.6%) 261/5,055 (5.2%) 594/4,139 (1.7%) 1,988/34,158 (5.8%) <0.001 <0.001 1.00 (0.80-1.24) 1.17 (1.03-1.33) 1.0 0.01